Targets and investigative treatments for primary biliary cholangitis

Ahmad H. Ali, Elizabeth J. Carey, Keith Lindor

Research output: Contribution to journalReview article

Abstract

Introduction: Primary biliary cholangitis (PBC) is an autoimmune disease of the liver that can slowly progress to cirrhosis, end-stage liver disease and its consequent complications. Areas covered: Ursodeoxycholic acid (UDCA) is approved for the treatment of PBC at a daily dose of 13 to 15 mg/kg/day, and should be continued indefinitely unless intolerance to UDCA occurs. Nearly 40% of patients have inadequate response to UDCA; therefore, there is a compelling need for newer and more effective therapies. Research has led to the discovery of several novel pathways that are thought to be implicated in the pathogenesis of PBC. Phase II and III clinical trials of obeticholic acid (OCA), the leading farnesoid X receptor agonist compound, in PBC patients with inadequate response to UDCA have shown that the use of OCA results in significant improvement in liver biochemistries. OCA has been recently recommended by the FDA’s Advisory Board for approval for treatment of PBC. Expert opinion: PBC remains a medical and socioeconomic problem. UDCA is currently the only medication approved for treatment of PBC. The discovery of novel therapeutic targets in PBC will hopefully lead to better outcomes in PBC.

Original languageEnglish (US)
Pages (from-to)1011-1020
Number of pages10
JournalExpert Opinion on Orphan Drugs
Volume4
Issue number10
DOIs
StatePublished - Oct 2 2016

Fingerprint

Cholangitis
Ursodeoxycholic Acid
Therapeutics
Phase III Clinical Trials
Phase II Clinical Trials
End Stage Liver Disease
Liver
Expert Testimony
Biochemistry
Autoimmune Diseases
Fibrosis

Keywords

  • antimitochondrial antibody
  • cirrhosis
  • end-stage liver disease
  • farnesoid X receptor
  • liver transplantation
  • obeticholic acid
  • Primary biliary cholangitis
  • ursodeoxycholic acid

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Cite this

Targets and investigative treatments for primary biliary cholangitis. / Ali, Ahmad H.; Carey, Elizabeth J.; Lindor, Keith.

In: Expert Opinion on Orphan Drugs, Vol. 4, No. 10, 02.10.2016, p. 1011-1020.

Research output: Contribution to journalReview article

Ali, Ahmad H. ; Carey, Elizabeth J. ; Lindor, Keith. / Targets and investigative treatments for primary biliary cholangitis. In: Expert Opinion on Orphan Drugs. 2016 ; Vol. 4, No. 10. pp. 1011-1020.
@article{35087bbf64dd4015b7f8f9a8b82f786e,
title = "Targets and investigative treatments for primary biliary cholangitis",
abstract = "Introduction: Primary biliary cholangitis (PBC) is an autoimmune disease of the liver that can slowly progress to cirrhosis, end-stage liver disease and its consequent complications. Areas covered: Ursodeoxycholic acid (UDCA) is approved for the treatment of PBC at a daily dose of 13 to 15 mg/kg/day, and should be continued indefinitely unless intolerance to UDCA occurs. Nearly 40{\%} of patients have inadequate response to UDCA; therefore, there is a compelling need for newer and more effective therapies. Research has led to the discovery of several novel pathways that are thought to be implicated in the pathogenesis of PBC. Phase II and III clinical trials of obeticholic acid (OCA), the leading farnesoid X receptor agonist compound, in PBC patients with inadequate response to UDCA have shown that the use of OCA results in significant improvement in liver biochemistries. OCA has been recently recommended by the FDA’s Advisory Board for approval for treatment of PBC. Expert opinion: PBC remains a medical and socioeconomic problem. UDCA is currently the only medication approved for treatment of PBC. The discovery of novel therapeutic targets in PBC will hopefully lead to better outcomes in PBC.",
keywords = "antimitochondrial antibody, cirrhosis, end-stage liver disease, farnesoid X receptor, liver transplantation, obeticholic acid, Primary biliary cholangitis, ursodeoxycholic acid",
author = "Ali, {Ahmad H.} and Carey, {Elizabeth J.} and Keith Lindor",
year = "2016",
month = "10",
day = "2",
doi = "10.1080/21678707.2016.1227240",
language = "English (US)",
volume = "4",
pages = "1011--1020",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Targets and investigative treatments for primary biliary cholangitis

AU - Ali, Ahmad H.

AU - Carey, Elizabeth J.

AU - Lindor, Keith

PY - 2016/10/2

Y1 - 2016/10/2

N2 - Introduction: Primary biliary cholangitis (PBC) is an autoimmune disease of the liver that can slowly progress to cirrhosis, end-stage liver disease and its consequent complications. Areas covered: Ursodeoxycholic acid (UDCA) is approved for the treatment of PBC at a daily dose of 13 to 15 mg/kg/day, and should be continued indefinitely unless intolerance to UDCA occurs. Nearly 40% of patients have inadequate response to UDCA; therefore, there is a compelling need for newer and more effective therapies. Research has led to the discovery of several novel pathways that are thought to be implicated in the pathogenesis of PBC. Phase II and III clinical trials of obeticholic acid (OCA), the leading farnesoid X receptor agonist compound, in PBC patients with inadequate response to UDCA have shown that the use of OCA results in significant improvement in liver biochemistries. OCA has been recently recommended by the FDA’s Advisory Board for approval for treatment of PBC. Expert opinion: PBC remains a medical and socioeconomic problem. UDCA is currently the only medication approved for treatment of PBC. The discovery of novel therapeutic targets in PBC will hopefully lead to better outcomes in PBC.

AB - Introduction: Primary biliary cholangitis (PBC) is an autoimmune disease of the liver that can slowly progress to cirrhosis, end-stage liver disease and its consequent complications. Areas covered: Ursodeoxycholic acid (UDCA) is approved for the treatment of PBC at a daily dose of 13 to 15 mg/kg/day, and should be continued indefinitely unless intolerance to UDCA occurs. Nearly 40% of patients have inadequate response to UDCA; therefore, there is a compelling need for newer and more effective therapies. Research has led to the discovery of several novel pathways that are thought to be implicated in the pathogenesis of PBC. Phase II and III clinical trials of obeticholic acid (OCA), the leading farnesoid X receptor agonist compound, in PBC patients with inadequate response to UDCA have shown that the use of OCA results in significant improvement in liver biochemistries. OCA has been recently recommended by the FDA’s Advisory Board for approval for treatment of PBC. Expert opinion: PBC remains a medical and socioeconomic problem. UDCA is currently the only medication approved for treatment of PBC. The discovery of novel therapeutic targets in PBC will hopefully lead to better outcomes in PBC.

KW - antimitochondrial antibody

KW - cirrhosis

KW - end-stage liver disease

KW - farnesoid X receptor

KW - liver transplantation

KW - obeticholic acid

KW - Primary biliary cholangitis

KW - ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=84988929462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988929462&partnerID=8YFLogxK

U2 - 10.1080/21678707.2016.1227240

DO - 10.1080/21678707.2016.1227240

M3 - Review article

VL - 4

SP - 1011

EP - 1020

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 10

ER -